Iovance Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:2LB Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
20 Feb 24	Buy€270,635	Iain Dukes	Individual	32,000	€8.46
20 Feb 24	Buy€2,114,336	Merrill McPeak	Individual	250,000	€8.46
20 Feb 24	Buy€42,286,725	Wayne Rothbaum	Individual	5,000,000	€8.46

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 2LB?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	29,353,918	9.63%
General Public	37,272,949	12.2%
VC/PE Firms	50,614,812	16.6%
Institutions	187,539,111	61.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.1%.

Top Shareholders

Top 25 shareholders own 71.85% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
9.21%	Wayne Rothbaum	28,067,333	€202.5m	0%	no data
8.96%	The Vanguard Group, Inc.	27,313,967	€197.1m	5.25%	no data
8.73%	Perceptive Advisors LLC	26,617,709	€192.0m	2.64%	4.55%
7.87%	MHR Fund Management LLC	23,997,103	€173.1m	0%	19.61%
7.05%	BlackRock, Inc.	21,483,668	€155.0m	1.22%	no data
4.33%	State Street Global Advisors, Inc.	13,201,978	€95.3m	4.57%	no data
2.94%	T. Rowe Price Group, Inc.	8,964,191	€64.7m	62%	0.01%
2.8%	Soleus Capital Management, L.P.	8,528,500	€61.5m	13%	4.8%
2.67%	Hood River Capital Management LLC	8,144,637	€58.8m	198%	0.92%
1.85%	Geode Capital Management, LLC	5,648,995	€40.8m	-2.38%	no data
1.58%	Artisan Partners Limited Partnership	4,803,825	€34.7m	-6.02%	0.03%
1.49%	Long Focus Capital Management LLC	4,532,000	€32.7m	9.68%	2.88%
1.47%	Balyasny Asset Management L.P.	4,472,576	€32.3m	-1.5%	0.09%
1.39%	Avoro Capital Advisors LLC	4,240,000	€30.6m	-63.8%	0.43%
1.32%	Principal Global Investors, LLC	4,033,184	€29.1m	59%	0.01%
1.25%	Goldman Sachs Group, Investment Banking and Securities Investments	3,805,528	€27.5m	69.4%	0.01%
1.05%	Macquarie Investment Management Business Trust	3,190,036	€23.0m	2,510%	0.03%
1%	Palo Alto Investors LP	3,041,685	€21.9m	43.7%	3.13%
0.84%	UBS Asset Management AG	2,568,971	€18.5m	-7.91%	no data
0.79%	BioImpact Capital LLC	2,406,714	€17.4m	1.69%	3.02%
0.74%	Northern Trust Global Investments	2,248,576	€16.2m	3.77%	no data
0.68%	Dimensional Fund Advisors LP	2,069,592	€14.9m	-8.65%	no data
0.66%	Bank of America Corporation, Asset Management Arm	2,014,518	€14.5m	-2.21%	no data
0.63%	Charles Schwab Investment Management, Inc.	1,913,144	€13.8m	-3.62%	no data
0.55%	Rice Hall James & Associates, LLC	1,679,157	€12.1m	2.64%	0.65%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 12:31
End of Day Share Price	2025/01/02 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Iovance Biotherapeutics, Inc. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Colleen Kusy	Baird
Madhu Kumar	Baird
Peter Lawson	Barclays